Vigonvita Life Sciences Co., Ltd. (Vigonvita) announced that it has received a letter from its independent auditor, Deloitte Touche Tohmatsu, dated 22 May 2026, confirming the Group’s compliance with Listing Rule 14A.56 requirements for its 2025 continuing connected transactions.

According to Deloitte’s review, the Group’s purchases of active pharmaceutical ingredients (API) and related ancillary services during 2025:

1. Secured prior approval from Vigonvita’s Board of Directors. 2. Were executed, in all material respects, in accordance with the governing agreements. 3. Remained within the annual caps set out in the Company’s prospectus.

The Board further clarified that these transactions did not involve the provision of goods or services by Vigonvita to connected parties. Apart from the supplemental auditor confirmation, no other information in the Company’s 2025 Annual Report has been amended.

This announcement carries no impact on previously disclosed financial statements or other operational data. Vigonvita’s Board reiterated that all other disclosures in the Annual Report issued on 30 April 2026 remain unchanged.